


WHAT IS CLAIMED IS:

1. The compound of Formula I:



5 wherein:

A is a bond, C(R²)₂, O, S(O)m or NR²;

B is (C(R²)₂);

10

D is O;

R¹ is selected from:

15

1) H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-6 cycloalkyl, and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:

20

- a) C₁-6 alkyl,
- b) C₃-6 cycloalkyl,
- c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- f) (F)pC₁₋₃ alkyl,

- g) halogen,
- h) OR⁴,
- i) O(CH₂)_s OR⁴,
- j) CO₂R⁴,
- 5 k) (CO)NR¹⁰R¹¹,
- l) O(CO)NR¹⁰R¹¹,
- m) N(R⁴)(CO)NR¹⁰R¹¹,
- n) N(R¹⁰)(CO)R¹¹,
- 10 o) N(R¹⁰)(CO)OR¹¹,
- p) SO₂NR¹⁰R¹¹,
- q) N(R¹⁰)SO₂R¹¹,
- r) S(O)_mR¹⁰,
- s) CN,
- t) NR¹⁰R¹¹,
- 15 u) N(R¹⁰)(CO)NR⁴R¹¹, and,
- v) O(CO)R⁴;

2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:

- 20 a) C₁-6 alkyl,
- b) C₃-6 cycloalkyl,
- c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- 25 e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- f) (F)pC₁-3 alkyl,
- g) halogen,
- 30 h) OR⁴,
- i) O(CH₂)_sOR⁴,
- j) CO₂R⁴,
- k) (CO)NR¹⁰R¹¹,

- l) $O(CO)NR^{10}R^{11}$,
- m) $N(R^4)(CO)NR^{10}R^{11}$,
- n) $N(R^{10})(CO)R^{11}$,
- o) $N(R^{10})(CO)OR^{11}$,
- 5 p) $SO_2NR^{10}R^{11}$,
- q) $N(R^{10})SO_2R^{11}$,
- r) $S(O)_mR^{10}$,
- s) CN ,
- v) $NR^{10}R^{11}$,
- 10 w) $N(R^{10})(CO)NR^4R^{11}$, and
- v) $O(CO)R^4$;

R^2 is independently selected from:

- 15 1) H, C₀-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-6 cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:
- a) C₁-6 alkyl,
- b) C₃-6 cycloalkyl,
- 20 c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- 25 f) (F)_pC₁-3 alkyl,
- g) halogen,
- h) OR⁴,
- i) O(CH₂)_sOR⁴,
- j) CO₂R⁴,
- 30 k) (CO)NR¹⁰R¹¹,
- l) O(CO)NR¹⁰R¹¹,
- m) N(R⁴)(CO)NR¹⁰R¹¹,

- n) $N(R^{10})(CO)R^{11}$,
- o) $N(R^{10})(CO)OR^{11}$,
- p) $SO_2NR^{10}R^{11}$,
- q) $N(R^{10})SO_2R^{11}$,
- 5 r) $S(O)_mR^{10}$,
- s) CN ,
- t) $NR^{10}R^{11}$,
- u) $N(R^{10})(CO)NR^4R^{11}$, and,
- v) $O(CO)R^4$; and,

10

- 2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:
 - a) C₁₋₆ alkyl,
 - b) C₃₋₆ cycloalkyl,
 - 15 c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
 - d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
 - e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
 - 20 f) (F)_pC₁₋₃ alkyl,
 - g) halogen,
 - h) OR⁴,
 - i) O(CH₂)_sOR⁴,
 - j) CO₂R⁴,
 - 25 k) (CO)NR¹⁰R¹¹,
 - l) O(CO)NR¹⁰R¹¹,
 - m) N(R⁴)(CO)NR¹⁰R¹¹,
 - n) N(R^{10})(CO)R¹¹,}
 - 30 o) N(R^{10})(CO)OR¹¹,}
 - p) SO₂NR¹⁰R¹¹,
 - q) N(R^{10})SO₂R¹¹,}
 - r) S(O)_mR¹⁰,

- s) CN,
- t) NR¹⁰R¹¹,
- u) N(R¹⁰)(CO)NR⁴R¹¹, and
- v) O(CO)R⁴;

5

or, any two independent R² on the same carbon or on adjacent carbons may be joined together to form a ring selected from cyclobutyl, cyclopentenyl, cyclopentyl, cyclohexenyl, cyclohexyl, thiazolinyl, oxazolinyl, imidazolinyl, imidazolidinyl, pyrrolinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, 10 tetrahydropyranyl, tetrahydropyridyl, furanyl, dihydrofuranyl, dihydropyranyl or piperazinyl,

where said ring is unsubstituted or substituted with 1-5 substituents independently selected from:

- (a) -C₁₋₆alkyl, which is unsubstituted or substituted with 1-3 substituents independently selected from:
 - (i) halo,
 - (ii) hydroxy,
 - (iii) -O-C₁₋₆alkyl,
 - (iv) -C₃₋₆cycloalkyl,
 - (v) -COR¹⁰
 - (vi) -CO₂R¹⁰,
 - (vii) -NR¹⁰R¹¹,
 - (viii) -SO₂R¹⁰,
 - (ix) -CONR¹⁰R¹¹, and
 - (x) -(NR¹⁰)CO₂R¹¹,
- (b) -SO₂NR¹⁰R¹¹
- (c) halo,
- (d) -SO₂R¹⁰,
- (e) hydroxy,
- (f) -O-C₁₋₆alkyl, which is unsubstituted or substituted with 1-5 halo,
- (g) -CN,
- (h) -COR¹⁰,
- (i) -NR¹⁰R¹¹,
- (j) -CONR¹⁰R¹¹,

- (k) $-\text{CO}_2\text{R}^{10}$,
- (l) $-(\text{NR}^{10})\text{CO}_2\text{R}^{11}$,
- (m) $-\text{O}(\text{CO})\text{NR}^{10}\text{R}^{11}$,
- (n) $-(\text{NR}^4)(\text{CO})\text{NR}^{10}\text{R}^{11}$, and
- 5 (o) oxo;

R^{10} and R^{11} are independently selected from: H, C₁₋₆ alkyl, (F)pC₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, heteroaryl, and benzyl, unsubstituted or substituted with halogen, hydroxy or C_{1-C6} alkoxy, where R¹⁰ and R¹¹ may be joined together to form a ring selected from: azetidinyl, pyrrolidinyl, piperidinyl, 10 piperazinyl, or morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴ ;

R⁴ is independently selected from: H, C₁₋₆ alkyl, (F)pC₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C_{1-C6} alkoxy;

15 W is O, NR⁴ or C(R⁴)₂;

X is C or S;

20 Y is O, (R⁴)₂, NCN, NSO₂CH₃, or NCONH₂, or Y is O₂ when X is S;

R⁵ is independently selected from H and:

- 1) C_{1-C6} alkyl, C_{2-C6} alkenyl, C_{2-C6} alkynyl, C₃₋₆ cycloalkyl and heterocycle, 25 unsubstituted or substituted with one or more substituents independently selected from:
 - a) C₁₋₆ alkyl,
 - b) C₃₋₆ cycloalkyl,
 - c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- 30 d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- f) (F)pC₁₋₃ alkyl,

- g) halogen,
- h) OR⁴,
- i) O(CH₂)_sOR⁴,
- j) CO₂R⁴,
- 5 k) (CO)NR¹⁰R¹¹,
- l) O(CO)NR¹⁰R¹¹,
- m) N(R⁴)(CO)NR¹⁰R¹¹,
- n) N(R¹⁰)(CO)R¹¹,
- 10 o) N(R¹⁰)(CO)OR¹¹,
- p) SO₂NR¹⁰R¹¹,
- q) N(R¹⁰)SO₂R¹¹,
- r) S(O)_mR¹⁰,
- s) CN,
- t) NR¹⁰R¹¹,
- 15 u) N(R¹⁰)(CO)NR⁴R¹¹, and,
- v) O(CO)R⁴;

- 2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:
 - a) C₁₋₆ alkyl,
 - b) C₃₋₆ cycloalkyl,
 - c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
 - d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
 - 25 e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
 - f) (F)_pC₁₋₃ alkyl,
 - g) halogen,
 - 30 h) OR⁴,
 - i) O(CH₂)_sOR⁴,
 - j) CO₂R⁴,
 - k) (CO)NR¹⁰R¹¹,
 - l) O(CO)NR¹⁰R¹¹,

- m) $N(R^4)(CO)NR^{10}R^{11}$,
- n) $N(R^{10})(CO)R^{11}$,
- o) $N(R^{10})(CO)OR^{11}$,
- p) $SO_2NR^{10}R^{11}$,
- 5 q) $N(R^{10})SO_2R^{11}$,
- r) $S(O)_mR^{10}$,
- s) CN ,
- t) $NR^{10}R^{11}$,
- 10 u) $N(R^{10})(CO)NR^4R^{11}$, and
- v) $O(CO)R^4$;

3) C_{1-6} alkyl,

4) C_{3-6} cycloalkyl,

15 5) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4 ,

6) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4 ,

7) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4 ,

8)

20 $(F)pC_{1-3}$ alkyl,

9) halogen,

10) OR^4 ,

11) $O(CH_2)_sOR^4$,

12) CO_2R^4 ,

25 13) $(CO)NR^{10}R^{11}$,

14) $O(CO)NR^{10}R^{11}$,

15) $N(R^4)(CO)NR^{10}R^{11}$,

16) $N(R^{10})(CO)R^{11}$,

17) $N(R^{10})(CO)OR^{11}$,

30 18) $SO_2NR^{10}R^{11}$,

19) $N(R^{10})SO_2R^{11}$,

20) $S(O)_mR^{10}$,

21) CN ,

22) $NR^{10}R^{11}$,

23) $\text{N}(\text{R}^{10})(\text{CO})\text{NR}^4\text{R}^{11}$, and,
 24) $\text{O}(\text{CO})\text{R}^4$,

or two R^5 attached to the same carbon form the substituent =O, such that $\text{C}(\text{R}^5)_2$ may be $\text{C}=\text{O}$,

5

where the number of R^5 substituents that are not H, can range from zero to three;

G-J is selected from: N, C, $\text{C}=\text{C}(\text{R}^5)$, $\text{N}-\text{C}(\text{R}^5)_2$, $\text{C}=\text{N}$, $\text{C}(\text{R}^5)-\text{C}(\text{R}^5)_2$, $\text{C}(\text{R}^5)-\text{N}(\text{R}^6)$,
 N(R^6)-N(R^6);

10

Q-T is selected from: $\text{C}(\text{R}^5)_2-\text{C}(\text{R}^5)_2$, $\text{C}(\text{R}^5)=\text{C}(\text{R}^5)$, $\text{N}=\text{C}(\text{R}^5)$, $\text{C}(\text{R}^5)=\text{N}$, $\text{N}=\text{N}$, N and $\text{C}(\text{R}^5)_2-$
 $(\text{C}=\text{O})$, $\text{N}(\text{R}^6)-(\text{C}=\text{O})$, $\text{C}(\text{R}^5)_2-\text{N}(\text{R}^6)$;

15

R^3 is independently selected from H, substituted or unsubstituted $\text{C}_1\text{-C}_3$ alkyl, CN and CO_2R^4 ;

20

p is 0 to $2q+1$, for a substituent with q carbons;

m is 0, 1 or 2;


n is 0 or 1;

s is 1, 2 or 3;

25

and pharmaceutically acceptable salts and individual diastereomers thereof.

2. A compound according to claim 1 having the Formula Ia:



wherein:

A is a bond, $\text{C}(\text{R}^2)_2$, O, $\text{S}(\text{O})_m$ or NR^2 ;


30 B is $(\text{C}(\text{R}^2)_2)_n$;

D is O;
n is 0 or 1; and

and pharmaceutically acceptable salts and individual stereoisomers thereof.

5

3. A compound according to claim 1 having the Formula Ib:




10

wherein:
A is a bond, C(R²)₂, O, S(O)_m or NR²;
B is (C(R²)₂)_n;
n is 0 or 1; and

15

and pharmaceutically acceptable salts and individual stereoisomers thereof.


4. A compound according to claim 1 having the Formula Ic:



20

and pharmaceutically acceptable salts and individual stereoisomers thereof.

5. A compound according to claim 1 having the Formula Id:

**Id**


wherein:

5 A is C(R²)₂, O, S(O)_m or NR²;

and pharmaceutically acceptable salts and individual stereoisomers thereof.

6. A compound according to claim 1 having the Formula Ie:

10

**Ie**

wherein:

15 A is C(R²)₂, O, S(O)_m or NR²;

and pharmaceutically acceptable salts and individual stereoisomers thereof.

7. A compound according to claim 1 having the Formulae Ia –Ie, wherein:

20

R¹ is selected from:

1) H, C₁-C₆ alkyl, C₃-6 cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:

25 a) C₁-6 alkyl,
b) C₃-6 cycloalkyl,

5 c) aryl, unsubstituted or substituted with 1-5 substituents where
the substituents are independently selected from R⁴,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents
where the substituents are independently selected from R⁴,
e) heterocycle, unsubstituted or substituted with 1-5 substituents
where the substituents are independently selected from R⁴,
f) (F)pC₁₋₃ alkyl,
g) halogen,
h) OR⁴,
10 i) O(CH₂)_sOR⁴,
j) CO₂R⁴,
k) CN,
l) NR¹⁰R¹¹, and
m) O(CO)R⁴; and

15 2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents
independently selected from:
a) C₁₋₆ alkyl,
b) C₃₋₆ cycloalkyl,
20 c) (F)pC₁₋₃ alkyl,
d) halogen,
e) OR⁴,
f) CO₂R⁴,
g) (CO)NR¹⁰R¹¹,
25 h) SO₂NR¹⁰R¹¹,
i) N(R¹⁰)SO₂R¹¹,
j) S(O)_mR⁴,
k) CN,
l) NR¹⁰R¹¹, and,
30 m) O(CO)R⁴;

R² is selected from:

35 1) H, C₀-C₆ alkyl, C₂-C₆ alkynyl, C₃₋₆ cycloalkyl and heterocycle, unsubstituted or
substituted with one or more substituents independently selected from:

a) C₁₋₆ alkyl,
b) C₃₋₆ cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
f) (F)_pC₁₋₃ alkyl,
g) halogen,
h) OR⁴,
i) O(CH₂)_sOR⁴,
j) CO₂R⁴,
k) S(O)_mR⁴,
l) CN,
m) NR¹⁰R¹¹, and
n) O(CO)R⁴; and

2) aryl or heteroaryl, unsubstituted or substituted with one more substituents independently selected from:
a) C₁₋₆ alkyl,
b) C₃₋₆ cycloalkyl,
c) (F)_pC₁₋₃ alkyl,
d) halogen,
e) OR⁴,
f) CO₂R⁴,
g) (CO)NR¹⁰R¹¹,
h) SO₂NR¹⁰R¹¹,
i) N(R¹⁰)SO₂R¹¹,
j) S(O)_mR⁴,
k) CN,
l) NR¹⁰R¹¹, and
m) O(CO)R⁴;

or, any two independent R² on the same carbon or on adjacent carbons may be joined together to form a ring selected from cyclobutyl, cyclopentenyl, cyclopentyl, cyclohexenyl, cyclohexyl, thiazolinyl, oxazolinyl, imidazolinyl, imidazolidinyl, pyrrolinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl,
5 tetrahydropyranyl, tetrahydropyridyl, furanyl, dihydrofuranyl, dihydropyranyl or piperazinyl,

where said ring is unsubstituted or substituted with 1-5 substituents independently selected from:

(a) -C₁₋₆alkyl, which is unsubstituted or substituted with 1-3 substituents
10 independently selected from:
(i) halo,
(ii) hydroxy,
(iii) -O-C₁₋₆alkyl,
(iv) -C₃₋₆cycloalkyl,
15 (v) -COR¹⁰,
(vi) -CO₂R¹⁰,
(vii) -NR¹⁰R¹¹,
(viii) -SO₂R¹⁰,
20 (ix) -CONR¹⁰R¹¹, and
(x) -(NR¹⁰)CO₂R¹¹,
(b) -SO₂NR¹⁰R¹¹,
(c) halo,
(d) -SO₂R¹⁰,
25 (e) hydroxy,
(f) -O-C₁₋₆alkyl, which is unsubstituted or substituted with 1-5 halo,
(g) -CN,
(h) -COR¹⁰,
(i) -NR¹⁰R¹¹,
30 (j) -CONR¹⁰R¹¹,
(k) -CO₂R¹⁰,
(l) -(NR¹⁰)CO₂R¹¹,
(m) -O(CO)NR¹⁰R¹¹,
(n) -(NR⁴)(CO)NR¹⁰R¹¹, and
(o) oxo;

R¹⁰ and R¹¹ are independently selected from: H, C₁₋₆ alkyl, (F)_pC₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C_{1-C6} alkoxy, where R¹⁰ and R¹¹ may be joined together to form a ring selected from: azetidinyl, pyrrolidinyl, piperidinyl, 5 piperazinyl and morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴

R⁴ is independently selected from: H, C₁₋₆ alkyl, (F)_pC₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C_{1-C6} alkoxy;

10

W is O, NR⁴ or C(R⁴)₂;

G-J and Q-T are selected from the following pairings:

15 G-J is N and Q-T is C(R⁵)₂ - C(R⁵)₂,

G-J is N, and Q-T is C(R⁵)=C(R⁵),

G-J is N and Q-T is N=C(R⁵),

20

G-J is N, and Q-T is C(R⁵)=N,

G-J is N, and Q-T is N=N,

25 G-J is C=C(R⁵), and Q-T is N(R⁶),

G-J is N, and Q-T is C(R⁵)₂ -(C=O)-,

G-J is N-C(R⁵)₂, and Q-T is C(R⁵)₂-C(R⁵)₂,

30

G-J is C=C(R⁵) and Q-T is C(R⁵)=C(R⁵),

G-J is C=C(R⁵), and Q-T is C(R⁵)=N,

G-J is C=C(R⁵), and Q-T is N=C(R⁵),

G-J is C=N, and Q-T is C(R⁵)=C(R⁵),

5 G-J is N-C(R⁵)₂, and QT is C(R⁵)₂-(C=O)-,

G-J is C(R⁵)-C(R⁵)₂, and QT is N(R⁶)-(C=O)-,

G-J is C(R⁵)-C(R⁵)₂, and QT is C(R⁵)₂-C(R⁵)₂,

10 G-J is C(R⁵)-C(R⁵)₂, and QT is C(R⁵)₂-N(R⁶),

G-J is C(R⁵)-N(R⁶), and QT is C(R⁵)₂-C(R⁵)₂,

15 G-J is C(R⁵)-C(R⁵)₂, and QT is N=C(R⁵),

G-J is N-C(R⁵)₂, and QT is C(R⁵)₂-N(R⁶),

G-J is N-N(R⁶), and QT is C(R⁵)₂-C(R⁵)₂, and

20 G-J is N-C(R⁵)₂, and QT is N=C(R⁵);

R⁵ is independently selected from H and:

25 1) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-6 cycloalkyl and heterocycle,
unsubstituted or substituted with one or more substituents independently selected from:
 a) C₁-6 alkyl,
 b) C₃-6 cycloalkyl,
 c) aryl, unsubstituted or substituted with 1-5 substituents where
the substituents are independently selected from R⁴,
 d) heteroaryl, unsubstituted or substituted with 1-5 substituents
where the substituents are independently selected from R⁴,

5 e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,

 f) (F)_pC₁₋₃ alkyl,

 g) halogen,

 h) OR⁴,

 i) O(CH₂)_sOR⁴,

 j) CO₂R⁴,

 k) (CO)NR¹⁰R¹¹,

 l) O(CO)NR¹⁰R¹¹,

 m) N(R⁴)(CO)NR¹⁰R¹¹,

 n) N(R¹⁰)(CO)R¹¹,

 o) N(R¹⁰)(CO)OR¹¹,

 p) SO₂NR¹⁰R¹¹,

 q) N(R¹⁰)SO₂R¹¹,

 r) S(O)_mR¹⁰,

 s) CN,

 t) NR¹⁰R¹¹,

 u) N(R¹⁰)(CO)NR⁴R¹¹, and,

 v) O(CO)R⁴;

20 2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:

 a) C₁₋₆ alkyl,

 b) C₃₋₆ cycloalkyl,

 c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,

 d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,

 e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,

 f) (F)_pC₁₋₃ alkyl,

 g) halogen,

 h) OR⁴,

 i) O(CH₂)_sOR⁴,

- j) CO_2R^4 ,
- k) $(\text{CO})\text{NR}^{10}\text{R}^{11}$,
- l) $\text{O}(\text{CO})\text{NR}^{10}\text{R}^{11}$,
- m) $\text{N}(\text{R}^4)(\text{CO})\text{NR}^{10}\text{R}^{11}$,
- 5 n) $\text{N}(\text{R}^{10})(\text{CO})\text{R}^{11}$,
- o) $\text{N}(\text{R}^{10})(\text{CO})\text{OR}^{11}$,
- p) $\text{SO}_2\text{NR}^{10}\text{R}^{11}$,
- q) $\text{N}(\text{R}^{10}) \text{SO}_2\text{R}^{11}$,
- r) $\text{S}(\text{O})_m\text{R}^{10}$,
- 10 s) CN ,
- t) $\text{NR}^{10}\text{R}^{11}$,
- u) $\text{N}(\text{R}^{10})(\text{CO})\text{NR}^4\text{R}^{11}$, and
- v) $\text{O}(\text{CO})\text{R}^4$;

15 3) C₁₋₆ alkyl,

4) C₃₋₆ cycloalkyl,

5) aryl, unsubstituted or substituted with 1-5 substituents where
the substituents are independently selected from R⁴,

20 6) heteroaryl, unsubstituted or substituted with 1-5 substituents
where the substituents are independently selected from R⁴,

7) heterocycle, unsubstituted or substituted with 1-5 substituents
where the substituents are independently selected from R⁴,

8) (F)_pC₁₋₃ alkyl,

9) halogen,

25 10) OR⁴,

11) O(CH₂)_sOR⁴,

12) CO₂R⁴,

13) (CO)NR¹⁰R¹¹,

14) O(CO)NR¹⁰R¹¹,

30 15) N(R^{4})(CO)NR¹⁰R¹¹,}

16) N(R^{10})(CO)R¹¹,}

17) N(R^{10})(CO)OR¹¹,}

18) SO₂NR¹⁰R¹¹,

19) N(R^{10}) SO₂R¹¹,}

20) $\text{S(O)}_m\text{R}^{10}$,
 21) CN,
 22) $\text{NR}^{10}\text{R}^{11}$,
 23) $\text{N}(\text{R}^{10})(\text{CO})\text{NR}^4\text{R}^{11}$, and,
 5 24) $\text{O}(\text{CO})\text{R}^4$,


or two R^5 attached to the same carbon form the substituent =O, such that $\text{C}(\text{R}^5)_2$ may be $\text{C}=\text{O}$,

where the number of R^5 substituents that are not H, can range from zero to three;

10 R^3 is independently selected from H, substituted or unsubstituted C₁-C₃ alkyl, CN and CO_2R^4 ;
 p is 0 to $2q+1$, for a substituent with q carbons
 m is 0 to 2;
 s is 1 to 3;

15 and pharmaceutically acceptable salts and individual stereoisomers thereof.

8. The compound of Formula II:



20

wherein:

B is independently $(\text{C}(\text{R}^2)_2)_n$;

25 D is O;

R^1 is selected from:

1) H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-6 cycloalkyl, and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:

5 a) C₁-6 alkyl,
 b) C₃-6 cycloalkyl,
 c) aryl, unsubstituted or substituted with 1-5 substituents where
 the substituents are independently selected from R⁴,
 d) heteroaryl, unsubstituted or substituted with 1-5 substituents
10 where the substituents are independently selected from R⁴,
 e) heterocycle, unsubstituted or substituted with 1-5 substituents
 where the substituents are independently selected from R⁴,
 f) (F)_pC₁-3 alkyl,
 g) halogen,
15 h) OR⁴,
 i) O(CH₂)_s OR⁴,
 j) CO₂R⁴,
 k) (CO)NR¹⁰R¹¹,
 l) O(CO)NR¹⁰R¹¹,
20 m) N(R⁴)(CO)NR¹⁰R¹¹,
 n) N(R¹⁰)(CO)R¹¹,
 o) N(R¹⁰)(CO)OR¹¹,
 p) SO₂NR¹⁰R¹¹,
 q) N(R¹⁰)SO₂R¹¹,
25 r) S(O)_mR¹⁰,
 s) CN,
 t) NR¹⁰R¹¹,
 u) N(R¹⁰)(CO)NR⁴R¹¹, and,
 v) O(CO)R⁴;

30 2) aryl or heteroaryl, unsubstituted or substituted with one or more
 substituents independently selected from:
 a) C₁-6 alkyl,
 b) C₃-6 cycloalkyl,

- c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- 5 e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- f) (F)_pC₁₋₃ alkyl,
- g) halogen,
- h) OR⁴,
- 10 i) O(CH₂)_sOR⁴,
- j) CO₂R⁴,
- k) (CO)NR¹⁰R¹¹,
- l) O(CO)NR¹⁰R¹¹,
- m) N(R⁴)(CO)NR¹⁰R¹¹,
- 15 n) N(R¹⁰)(CO)R¹¹,
- o) N(R¹⁰)(CO)OR¹¹,
- p) SO₂NR¹⁰R¹¹,
- q) N(R¹⁰)SO₂R¹¹,
- r) S(O)_mR¹⁰,
- 20 s) CN,
- x) NR¹⁰R¹¹,
- y) N(R¹⁰)(CO)NR⁴R¹¹, and
- v) O(CO)R⁴;

25 R² is independently selected from:

- 1) H, C₀-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-6 cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:
- 30 a) C₁₋₆ alkyl,
- b) C₃₋₆ cycloalkyl,
- c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,

- d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- 5 f) (F)_pC₁₋₃ alkyl,
- g) halogen,
- h) OR⁴,
- i) O(CH₂)_sOR⁴,
- j) CO₂R⁴,
- 10 k) (CO)NR¹⁰R¹¹,
- l) O(CO)NR¹⁰R¹¹,
- m) N(R⁴)(CO)NR¹⁰R¹¹,
- n) N(R¹⁰)(CO)R¹¹,
- 15 o) N(R¹⁰)(CO)OR¹¹,
- p) SO₂NR¹⁰R¹¹,
- q) N(R¹⁰)SO₂R¹¹,
- r) S(O)_mR¹⁰,
- s) CN,
- t) NR¹⁰R¹¹,
- 20 u) N(R¹⁰)(CO)NR⁴R¹¹, and,
- v) O(CO)R⁴;

- 2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:
 - 25 a) C₁₋₆ alkyl,
 - b) C₃₋₆ cycloalkyl,
 - c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
 - d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
 - 30 e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
 - f) (F)_pC₁₋₃ alkyl,
 - g) halogen,

- h) OR⁴,
- i) O(CH₂)_sOR⁴,
- j) CO₂R⁴,
- k) (CO)NR¹⁰R¹¹,
- 5 l) O(CO)NR¹⁰R¹¹,
- m) N(R⁴)(CO)NR¹⁰R¹¹,
- n) N(R¹⁰)(CO)R¹¹,
- 10 o) N(R¹⁰)(CO)OR¹¹,
- p) SO₂NR¹⁰R¹¹,
- q) N(R¹⁰)SO₂R¹¹,
- r) S(O)_mR¹⁰,
- s) CN,
- t) NR¹⁰R¹¹,
- 15 u) N(R¹⁰)(CO)NR⁴R¹¹, and
- v) O(CO)R⁴;

or, the independent R² on adjacent carbons may be joined together to form a ring selected from cyclopentenyl, cyclohexenyl, phenyl, naphthyl, thienyl, thiazolyl, thiazolinyl, oxazolyl, oxazolinyl, imidazolyl, imidazolinyl, pyridyl, pyrimidyl, pyrazinyl, pyrrolyl, pyrrolinyl, tetrahydropyridyl, furanyl, dihydrofuranyl and dihydropyranyl,

where said ring is unsubstituted or substituted with 1-5 substituents independently selected from:

- (a) -C1-6alkyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from:
 - (i) halo,
 - (ii) hydroxy,
 - (iii) -O-C1-6alkyl,
 - (iv) -C3-6cycloalkyl,
 - 25 (v) -COR¹⁰
 - (vi) -CO₂R¹⁰,
 - (vii) -NR¹⁰R¹¹,
 - (viii) -SO₂R¹⁰,
 - 30 (ix) -CONR¹⁰R¹¹, and

(x) -(NR₁₀)CO₂R₁₁,

(b) -SO₂NR₁₀R₁₁

(c) halo,

(d) -SO₂R₁₀,

5 (e) hydroxy,

(f) -O-C₁₋₆alkyl, which is unsubstituted or substituted with 1-5 halo,

(g) -CN,

(h) -COR₁₀,

(i) -NR₁₀R₁₁,

10 (j) -CONR₁₀R₁₁,

(k) -CO₂R₁₀,

(l) -(NR₁₀)CO₂R₁₁,

(m) -O(CO)NR₁₀R₁₁,

(n) -(NR₄)(CO)NR₁₀R₁₁, and

15 (o) oxo;

R¹⁰ and R¹¹ are independently selected from: H, C₁₋₆ alkyl, (F)pC₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, heteroaryl, and benzyl, unsubstituted or substituted with halogen, hydroxy or C_{1-C6} alkoxy, where R¹⁰ and R¹¹ may be joined together to form a ring selected from: azetidinyl, pyrrolidinyl, piperidinyl,
20 piperazinyl, or morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴ ;

25 R⁴ is independently selected from: H, C₁₋₆ alkyl, (F)pC₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C_{1-C6} alkoxy;

W is O, NR⁴ or C(R⁴)₂;

X is C or S;

30 Y is O, (R⁴)₂, NCN, NSO₂CH₃ or NCONH₂, or Y is O₂ when X is S;

R⁵ is independently selected from H and:

1) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:

5 a) C₁-6 alkyl,
 b) C₃-6 cycloalkyl,
 c) aryl, unsubstituted or substituted with 1-5 substituents where
 the substituents are independently selected from R⁴,
 d) heteroaryl, unsubstituted or substituted with 1-5 substituents
 where the substituents are independently selected from R⁴,
10 e) heterocycle, unsubstituted or substituted with 1-5 substituents
 where the substituents are independently selected from R⁴,
 f) (F)_pC₁-3 alkyl,
 g) halogen,
 h) OR⁴,
15 i) O(CH₂)_sOR⁴,
 j) CO₂R⁴,
 k) (CO)NR¹⁰R¹¹,
 l) O(CO)NR¹⁰R¹¹,
 m) N(R⁴)(CO)NR¹⁰R¹¹,
20 n) N(R¹⁰)(CO)R¹¹,
 o) N(R¹⁰)(CO)OR¹¹,
 p) SO₂NR¹⁰R¹¹,
 q) N(R¹⁰)SO₂R¹¹,
 r) S(O)_mR¹⁰,
25 s) CN,
 t) NR¹⁰R¹¹,
 u) N(R¹⁰)(CO)NR⁴R¹¹, and,
 v) O(CO)R⁴;

30 2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents
 independently selected from:
 a) C₁-6 alkyl,
 b) C₃-6 cycloalkyl,

- c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- 5 e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- f) (F)_pC₁₋₃ alkyl,
- g) halogen,
- 10 h) OR⁴,
- i) O(CH₂)_sOR⁴,
- j) CO₂R⁴,
- k) (CO)NR¹⁰R¹¹,
- 15 l) O(CO)NR¹⁰R¹¹,
- m) N(R⁴)(CO)NR¹⁰R¹¹,
- n) N(R¹⁰)(CO)R¹¹,
- o) N(R¹⁰)(CO)OR¹¹,
- p) SO₂NR¹⁰R¹¹,
- q) N(R¹⁰)SO₂R¹¹,
- r) S(O)_mR¹⁰,
- 20 s) CN,
- t) NR¹⁰R¹¹,
- u) N(R¹⁰)(CO)NR⁴R¹¹, and
- v) O(CO)R⁴;

- 25 3) C₁₋₆ alkyl,
- 4) C₃₋₆ cycloalkyl,
- 5) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- 6) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- 30 7) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- 8) (F)_pC₁₋₃ alkyl,
- 9) halogen,

- 10) OR⁴,
- 11) O(CH₂)_sOR⁴,
- 12) CO₂R⁴,
- 13) (CO)NR¹⁰R¹¹,
- 5 14) O(CO)NR¹⁰R¹¹,
- 15) N(R⁴)(CO)NR¹⁰R¹¹,
- 16) N(R¹⁰)(CO)R¹¹,
- 17) N(R¹⁰)(CO)OR¹¹,
- 18) SO₂NR¹⁰R¹¹,
- 10 19) N(R¹⁰)SO₂R¹¹,
- 20) S(O)_mR¹⁰,
- 21) CN,
- 22) NR¹⁰R¹¹,
- 23) N(R¹⁰)(CO)NR⁴R¹¹, and,
- 15 24) O(CO)R⁴,

or two R⁵ attached to the same carbon form the substituent =O, such that C(R⁵)₂ may be C=O,

where the number of R⁵ substituents that are not H, can range from zero to three;

20 G-J is selected from: N, C, C=C(R⁵), N-C(R⁵)₂, C=N, C(R⁵)-C(R⁵)₂, C(R⁵)-N(R⁶), N(R⁶)-N(R⁶);

25 Q-T is selected from: C(R⁵)₂-C(R⁵)₂, C(R⁵)=C(R⁵), N=C(R⁵), C(R⁵)=N, N=N, N and C(R⁵)₂-(C=O), N(R⁶)-(C=O), C(R⁵)₂-N(R⁶);

R³ is independently selected from H, substituted or unsubstituted C₁-C₃ alkyl, CN and CO₂R⁴;

p is	0 to 2q+1, for a substituent with q carbons;
30 m is	0, 1 or 2;
n is	0 or 1;
s is	1, 2 or 3;

and pharmaceutically acceptable salts and individual diastereomers thereof.

9. A compound according to claim 8, wherein:

R¹ is selected from:

5

- 1) H, C₁-C₆ alkyl, C₃-6 cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:
 - a) C₁-6 alkyl,
 - b) C₃-6 cycloalkyl,
 - c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
 - d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
 - e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
 - f) (F)pC₁-3 alkyl,
 - g) halogen,
 - h) OR⁴,
 - i) O(CH₂)_sOR⁴,
 - j) CO₂R⁴,
 - k) CN,
 - l) NR¹⁰R¹¹, and
 - m) O(CO)R⁴; and
- 25 2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:
 - a) C₁-6 alkyl,
 - b) C₃-6 cycloalkyl,
 - c) (F)pC₁-3 alkyl,
 - 30 d) halogen,
 - e) OR⁴,
 - f) CO₂R⁴,
 - g) (CO)NR¹⁰R¹¹,
 - h) SO₂NR¹⁰R¹¹,
 - 35 i) N(R¹⁰)SO₂R¹¹,

- j) $S(O)_m R^4$,
- k) CN,
- l) $NR^{10}R^{11}$, and,
- m) O(CO) R^4 ;

5

R^2 is selected from:

- 1) H, C_0-C_6 alkyl, C_2-C_6 alkynyl, C_3-6 cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:
 - a) C_{1-6} alkyl,
 - b) C_{3-6} cycloalkyl,
 - c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4 ,
 - d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4 ,
 - e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4 ,
 - f) $(F)_p C_{1-3}$ alkyl,
 - g) halogen,
 - h) OR^4 ,
 - i) $O(CH_2)_s OR^4$,
 - j) CO_2R^4 ,
 - k) $S(O)_m R^4$,
 - l) CN,
 - 25 m) $NR^{10}R^{11}$, and
 - n) O(CO) R^4 ; and

- 2) aryl or heteroaryl, unsubstituted or substituted with one more substituents independently selected from:
 - a) C_{1-6} alkyl,
 - b) C_{3-6} cycloalkyl,
 - c) $(F)_p C_{1-3}$ alkyl,
 - d) halogen,
 - e) OR^4 ,
 - 30 f) CO_2R^4 .

- g) $(CO)NR^{10}R^{11}$,
- h) $SO_2NR^{10}R^{11}$,
- i) $N(R^{10})SO_2R^{11}$,
- j) $S(O)_mR^4$,
- 5 k) CN ,
- l) $NR^{10}R^{11}$, and
- m) $O(CO)R^4$;

R^{10} and R^{11} are independently selected from: H, C₁₋₆ alkyl, (F)pC₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C_{1-C6} alkoxy, where R^{10} and R^{11} may be joined together to form a ring selected from: azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4

15 R^4 is independently selected from: H, C₁₋₆ alkyl, (F)pC₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C_{1-C6} alkoxy;

W is O, NR⁴ or C(R⁴)₂;

20 G-J and Q-T are selected from the following pairings:

G-J is N and Q-T is C(R⁵)₂ - C(R⁵)₂,

25 G-J is N, and Q-T is C(R⁵)=C(R⁵),

G-J is N and Q-T is N=C(R⁵),

G-J is N, and Q-T is C(R⁵)=N,

30 G-J is N, and Q-T is N=N,

G-J is C=C(R⁵), and Q-T is N(R⁶),

G-J is N, and Q-T is C(R⁵)₂ -(C=O)-,

G-J is N-C(R⁵)₂, and Q-T is C(R⁵)₂-C(R⁵)₂,

G-J is C=C(R⁵) and Q-T is C(R⁵)=C(R⁵),

5

G-J is C=C(R⁵), and Q-T is C(R⁵)=N,

G-J is C=C(R⁵), and Q-T is N=C(R⁵),

10

G-J is C=N, and Q-T is C(R⁵)=C(R⁵),

G-J is N-C(R⁵)₂, and QT is C(R⁵)₂-(C=O)-,

G-J is C(R⁵)-C(R⁵)₂, and QT is N(R⁶)-(C=O)-,

15

G-J is C(R⁵)-C(R⁵)₂, and QT is C(R⁵)₂-C(R⁵)₂,

G-J is C(R⁵)-C(R⁵)₂, and QT is C(R⁵)₂-N(R⁶),

20

G-J is C(R⁵)-N(R⁶), and QT is C(R⁵)₂-C(R⁵)₂,

G-J is C(R⁵)-C(R⁵)₂, and QT is N=C(R⁵),

G-J is N-C(R⁵)₂, and QT is C(R⁵)₂-N(R⁶),

25

G-J is N-N(R⁶), and QT is C(R⁵)₂-C(R⁵)₂, and

G-J is N-C(R⁵)₂, and QT is N=C(R⁵);

30 R⁵ is independently selected from H and:

- 1) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:

- a) C₁₋₆ alkyl,
- b) C₃₋₆ cycloalkyl,
- c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- 5 d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
- f) (F)_pC₁₋₃ alkyl,
- 10 g) halogen,
- h) OR⁴,
- i) O(CH₂)_sOR⁴,
- j) CO₂R⁴,
- k) (CO)NR¹⁰R¹¹,
- 15 l) O(CO)NR¹⁰R¹¹,
- m) N(R⁴)(CO)NR¹⁰R¹¹,
- n) N(R¹⁰)(CO)R¹¹,
- o) N(R¹⁰)(CO)OR¹¹,
- p) SO₂NR¹⁰R¹¹,
- 20 q) N(R¹⁰)SO₂R¹¹,
- r) S(O)_mR¹⁰,
- s) CN,
- t) NR¹⁰R¹¹,
- u) N(R¹⁰)(CO)NR⁴R¹¹, and,
- 25 v) O(CO)R⁴;

- 2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:
 - a) C₁₋₆ alkyl,
 - b) C₃₋₆ cycloalkyl,
 - c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,
 - d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,

5 e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,

 f) (F)_pC₁₋₃ alkyl,

 g) halogen,

 h) OR⁴,

 i) O(CH₂)_sOR⁴,

 j) CO₂R⁴,

 k) (CO)NR¹⁰R¹¹,

 l) O(CO)NR¹⁰R¹¹,

 m) N(R⁴)(CO)NR¹⁰R¹¹,

 n) N(R¹⁰)(CO)R¹¹,

 o) N(R¹⁰)(CO)OR¹¹,

 p) SO₂NR¹⁰R¹¹,

 q) N(R¹⁰)SO₂R¹¹,

 r) S(O)_mR¹⁰,

 s) CN,

 t) NR¹⁰R¹¹,

 u) N(R¹⁰)(CO)NR⁴R¹¹, and

 v) O(CO)R⁴;

20

3) C₁₋₆ alkyl,

4) C₃₋₆ cycloalkyl,

5) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,

25 6) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,

 7) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R⁴,

 8) (F)_pC₁₋₃ alkyl,

30 9) halogen,

 10) OR⁴,

 11) O(CH₂)_sOR⁴,

 12) CO₂R⁴,

 13) (CO)NR¹⁰R¹¹,

14) $O(CO)NR^{10}R^{11}$,
 15) $N(R^4)(CO)NR^{10}R^{11}$,
 16) $N(R^{10})(CO)R^{11}$,
 17) $N(R^{10})(CO)OR^{11}$,
 5 18) $SO_2NR^{10}R^{11}$,
 19) $N(R^{10})SO_2R^{11}$,
 20) $S(O)_mR^{10}$,
 21) CN ,
 22) $NR^{10}R^{11}$,
 10 23) $N(R^{10})(CO)NR^4R^{11}$, and,
 24) $O(CO)R^4$,

or two R^5 attached to the same carbon form the substituent $=O$, such that $C(R^5)_2$ may be $C=O$,

15 where the number of R^5 substituents that are not H, can range from zero to three;

R^3 is independently selected from H, substituted or unsubstituted C₁-C₃ alkyl, CN and CO_2R^4 ;

p is 0 to $2q+1$, for a substituent with q carbons


m is 0 to 2;


20 s is 1 to 3;


and pharmaceutically acceptable salts and individual stereoisomers thereof.


10. A compound selected from:


25











and pharmaceutically acceptable salts and individual diastereomers thereof.

5

11. A pharmaceutical composition which comprises an inert carrier and the compound of Claim 1.

12. A method for antagonism of CGRP receptor activity in a mammal which comprises the administration of an effective amount of the compound of Claim 1.

13. A method for treating, controlling, ameliorating or reducing the risk of headache, 5 migraine or cluster headache in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of the compound of Claim 1.